QurAlis
Cambridge, United States · Biotechnology, Healthcare, Health Care · 94 employees
QurAlis is a pioneering neuroscience company dedicated to developing precision medicines that target the root causes of neurodegenerative and neurological diseases. With leading expertise in amyotrophic lateral sclerosis (ALS), the company is committed to translating scientific breakthroughs into transformative therapies. Guided by collaboration, scientific rigor, and compassion, QurAlis is advanc
Funding history
- Funding Round — $20.0M — Sep 2025
- Funding Round — $60.0M — Mar 2023
- Funding Round — $88.0M — Mar 2023
- Funding Round — $5.0M — Sep 2022
- Funding Round — $33.2M — May 2020
Recent signals
- Nov 10, 2025: QurAlis Appoints Manoj Malhotra, M.D., as Chief Medical Officer
- Sep 05, 2025: Raised $20.0M
- Jun 13, 2024: QurAlis Appoints Doug Williamson and Jason Brown to Key Executive Positions
- Mar 13, 2023: Raised $60.0M
- Mar 09, 2023: Raised $88.0M
- Sep 01, 2022: Raised $5.0M
- May 18, 2020: Raised $33.2M
See plans & pricing → Track QurAlis’s funding, hiring, and signals — with verified contacts — on Fundz.